Seite - 46 - in Advances in Neuroimmunology
Bild der Seite - 46 -
Text der Seite - 46 -
BrainSci. 2016,6, 18
Sexdifferencecanplayarole inaffectingtheroleof IL-13 in theMSmodel.Whileautoimmune
diseases, includingMS,aremorecommoninwomen[76], the incidenceandseverityofEAEinmice,
null for IL-13,was lower infemalescomparedtomales, suggestingthepossibility that thecontribution
of IL-13toEAE/MSmaybegenderspecific[77]. Tothisend, it is interestingtonote that theexpression
of IL-13mRNAcanbedecreasedbyestrogen inamousemodelof inflammatory intestinedisease [78]
andthat thegeneencodingfor IL-13Rα1 is locatedontheXchromosomeinbothhumansandmice.
Together, thesestudiessuggest that IL-13mayhaveaneuroprotectiverole inMS.Althoughthis
may be different in other neurodegenerative diseases that, unlike MS, are not characterized by
aseverely-compromisedblood-brainbarrier,andarenotprimarilymediatedbyperipheral immune
cells, IL-13 and IL-4 also showed protection in a mouse model of Alzheimer’s disease (AD).
Specifically, intracerebral injectionof amixtureof IL-13and IL-4 reducedamyloiddepositionand
improvedspatial learningandmemory inanADtransgenicmousemodelwhenapplied toyoung
micebutdidnotshowprotectiveeffectswhenadministered inadultanimals [79].
6. Parkinson’sDisease
TheIL-13systemmayhaveaspecificroleinthepathogenesisand/ortheprogressionofParkinson’s
disease (PD).Dataminingusing theOnlineMendelian Inheritance inMan (OMIM)database [80]
showed that IL-13Rα1 lies within the PARK12 region of susceptibility to PD. Although PARK12
comprisesa largeportionofDNA, it is locatedontheXchromosome,anobservationthatmaybeof
interest in thatPDhasahigher incidence inmenthaninwomen.Evenmore intriguingwasthe finding
thatexpressionof IL-13Rα1 in thebrainappeared tobespecific to thedopaminergicneuronsof the
VTAandof theSNc, the regionaffectedbyPD.Double-immunostaining studies also revealed that
approximately80%of theSNcneuronsexpressingthedopaminergicmarker tyrosinehydroxylasealso
expressedIL-13Rα1[1].
Thepossiblecontributionof IL-13Rα1 toneuronal fatewasmeasuredusingapro-inflammatory
experimentalmousemodelofPD.Animals receivedperiodicperipheral intraperitoneal injectionsof
bacterialLPSoveraperiodofsixmonths,a regimenpreviouslydemonstratedto inducecentral loss
ofdopaminergicSNcneurons [81]. Comparativeanalysis showedthatmice lackingIL-13Rα1were
protectedfromneuronal losswhencomparedto theirwild-type littermates, suggestinganeurotoxic
actionof its ligands, IL-13and/or IL-4. Invitroexperimentsusingadopaminergiccell lineshowed,
however, thatneither IL-13nor IL-4hadcytotoxiceffectswhenadministeredalone.However,both
cytokines increasedthe toxicityofnon-toxicdosesofoxidants inadose-dependentmanner.
Thus, activation of IL-13Rα1 may be one of the mechanisms whereby the vulnerability of
dopaminergicneurons is increasedduring inflammation,whenbothcytokinesandROSareproduced.
On the other hand, the lack of neurotoxicity of IL-13 or IL-4 in the absence of ROS suggests that
thesecytokinesmaybecapableof regulatingneuronal functionbyaffecting theneurobiologyof those
neurons thatparticipate inreward,addiction,andmotorcontrol.
Investigating thesephenomena is likely toprovide important informationonthemechanismsof
howIL-13andIL-4and,moregenerally, the immunesystem,maybecapableof influencingbehavior
orcancontribute toneurodegeneration.
7.Conclusions
Although in its infancy, the investigationof thecentral roleof the interleukins13and4has is
anexcitingareaof research.Whatmakes it soattractive is that these twocytokinescanbeproduced
locally in theCNSandareactiveonbothmicrogliaandneuronalcells.Ofspecial interest is the fact
that theyact throughacommonheterodimeric receptor that isexpressed indopaminergicneurons.
Althoughthese twoTh2cytokinesareconsideredanti-inflammatory, studiesconductedsofarshow
that theycanhavecytotoxiceffectsonbothgliaandneurons. Interestingly theseactionsarenotdue to
an intrinsic toxicityof IL-13andIL-4but rather to theirability to increase thecellular susceptibility to
oxidativestress. Thissuggest thatunderpathological conditions, suchasneuroinflammationwhen
46
zurück zum
Buch Advances in Neuroimmunology"
Advances in Neuroimmunology
- Titel
- Advances in Neuroimmunology
- Autor
- Donna Gruol
- Herausgeber
- MDPI
- Ort
- Basel
- Datum
- 2017
- Sprache
- englisch
- Lizenz
- CC BY-NC-ND 4.0
- ISBN
- 978-3-03842-571-7
- Abmessungen
- 17.0 x 24.0 cm
- Seiten
- 164
- Schlagwörter
- neuroimmune, cytokine, chemokine, glia cel, neuron, neurodevelopment, neuroimmune disorder, neurologic disease, psychiatric disease, neuronal injury
- Kategorie
- Medizin